nach oben

Erschienen in:

01.10.2014 | Gastrointestinal

Hepatobiliary magnetic resonance imaging in patients with liver disease: correlation of liver enhancement with biochemical liver function tests

verfasst von: Guido M. Kukuk, Stephanie G. Schaefer, Rolf Fimmers, Dariusch R. Hadizadeh, Samer Ezziddin, Ulrich Spengler, Hans H. Schild, Winfried A. Willinek

Erschienen in: European Radiology | Ausgabe 10/2014

Einloggen, um Zugang zu erhalten

Abstract

Objectives

To evaluate hepatobiliary magnetic resonance imaging (MRI) using Gd-EOB-DTPA in relation to various liver function tests in patients with liver disorders.

Methods

Fifty-one patients with liver disease underwent Gd-EOB-DTPA-enhanced liver MRI. Based on region-of-interest (ROI) analysis, liver signal intensity was calculated using the spleen as reference tissue. Liver-spleen contrast ratio (LSCR) and relative liver enhancement (RLE) were calculated. Serum levels of total bilirubin, gamma glutamyl transpeptidase (GGT), aspartate aminotransferase (AST), alanine aminotransferase (ALT), glutamate dehydrogenase (GLDH), lactate dehydrogenase (LDH), serum albumin level (AL), prothrombin time (PT), creatinine (CR) as well as international normalised ratio (INR) and model for end-stage liver disease (MELD) score were tested for correlation with LSCR and RLE.

Results

Pre-contrast LSCR values correlated with total bilirubin (r = -0.39; p = 0.005), GGT (r = -0.37; p = 0.009), AST (r = -0.38; p = 0.013), ALT (r = -0.29; p = 0.046), PT (r = 0.52; p < 0.001), GLDH (r = -0.55; p = 0.044), INR (r = -0.42; p = 0.003), and MELD Score (r = -0.53; p < 0.001). After administration of Gd-EOB-DTPA bilirubin (r = -0.45; p = 0.001), GGT (r = -0.40; p = 0.004), PT (r = 0.54; p < 0.001), AST (r = -0.46; p = 0.002), ALT (r = -0.31; p = 0.030), INR (r = -0.45; p = 0.001) and MELD Score (r = -0.56; p < 0.001) significantly correlated with LSCR. RLE correlated with bilirubin (r = -0.40; p = 0.004), AST (r = -0.38; p = 0.013), PT (r = 0.42; p = 0.003), GGT (r = -0.33; p = 0.020), INR (r = -0.36; p = 0.011) and MELD Score (r = -0.43; p = 0.003).

Conclusions

Liver-spleen contrast ratio and relative liver enhancement using Gd-EOB-DTPA correlate with a number of routinely used biochemical liver function tests, suggesting that hepatobiliary MRI may serve as a valuable biomarker for liver function. The strongest correlation with liver enhancement was found for the MELD Score.

Key Points

• Relative enhancement (RLE) of Gd-EOB-DTPA is related to biochemical liver function tests.

• Correlation of RLE with bilirubin, ALT, AST, GGT, INR and MELD Score is reverse.

• The correlation of relative liver enhancement with prothrombin time is positive.

• AST, ALT, GLDH, prothrombin time, INR and MELD Score correlate with pre-contrast liver-spleen contrast ratio.

• Such biomarkers may help to evaluate liver function.

Pratt DS (2010) Liver chemistry and function tests. In: Feldman M, Friedman LS, Brandt LJ (eds) Sleisenger and Fordtran's gastrointestinal and liver diease. Saunders Elsevier, Philadelphia, pp 1227–1237CrossRef

Kamath PS, Kim WR (2007) The model for end-stage liver disease (MELD). Hepatology 45:797–805PubMedCrossRef

Nassif A, Jia J, Keiser M et al (2012) Visualization of hepatic uptake transporter function in healthy subjects by using gadoxetic acid-enhanced MR imaging. Radiology 264:741–750PubMedCrossRef

Jia J, Puls D, Oswald S et al (2014) Characterization of the intestinal and hepatic uptake/efflux transport of the magnetic resonance imaging contrast agent gadolinium-ethoxylbenzyl-diethylenetriamine-pentaacetic acid. Invest Radiol 49:78–86PubMedCrossRef

Golfieri R, Renzulli M, Lucidi V, Corcioni B, Trevisani F, Bolondi L (2011) Contribution of the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI to Dynamic MRI in the detection of hypovascular small (≤2 cm) HCC in cirrhosis. Eur Radiol 21:1233–1242PubMedCrossRef

Motosugi U, Ichikawa T, Sou H et al (2010) Distinguishing hypervascular pseudolesions of the liver from hypervascular hepatocellular carcinomas with gadoxetic acid-enhanced MR imaging. Radiology 256:151–158PubMedCrossRef

Vogl TJ, Kummel S, Hammerstingl R et al (1996) Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA. Radiology 200:59–67PubMedCrossRef

Scharitzer M, Ba-Ssalamah A, Ringl H et al (2013) Preoperative evaluation of colorectal liver metastases: comparison between gadoxetic acid-enhanced 3.0-T MRI and contrast-enhanced MDCT with histopathological correlation. Eur Radiol 23:2187–2196PubMedCrossRef

Kim T, Murakami T, Hasuike Y et al (1997) Experimental hepatic dysfunction: evaluation by MRI with Gd-EOB-DTPA. J Magn Reson Imaging 7:683–688PubMedCrossRef

10.

Shimizu J, Dono K, Gotoh M et al (1999) Evaluation of regional liver function by gadolinium-EOB-DTPA-enhanced MR imaging. Dig Dis Sci 44:1330–1337PubMedCrossRef

11.

Motosugi U, Ichikawa T, Sou H et al (2009) Liver parenchymal enhancement of hepatocyte-phase images in Gd-EOB-DTPA-enhanced MR imaging: which biological markers of the liver function affect the enhancement? J Magn Reson Imaging 30:1042–1046PubMedCrossRef

12.

Kubota K, Tamura T, Aoyama N et al (2012) Correlation of liver parenchymal gadolinium-ethoxybenzyl diethylenetriaminepentaacetic acid enhancement and liver function in humans with hepatocellular carcinoma. Oncol Lett 3:990–994PubMedCentralPubMed

13.

Van Beers BE, Pastor CM, Hussain HK (2012) Primovist, Eovist: what to expect? J Hepatol 57:421–429PubMedCrossRef

14.

Yamada A, Hara T, Li F et al (2011) Quantitative evaluation of liver function with use of gadoxetate disodium-enhanced MR imaging. Radiology 260:727–733PubMedCrossRef

15.

Ryeom HK, Kim SH, Kim JY et al (2004) Quantitative evaluation of liver function with MRI Using Gd-EOB-DTPA. Korean J Radiol 5:231–239PubMedCentralPubMedCrossRef

16.

Stockmann M, Lock JF, Malinowski M, Niehues SM, Seehofer D, Neuhaus P (2010) The LiMAx test: a new liver function test for predicting postoperative outcome in liver surgery. HPB (Oxford) 12:139–146CrossRef

17.

Garden OJ (2009) Hepatobiliary and pancreatic surgery. Companion to specialist surgical practice, 4th edn. Saunders Elsevier, Philadelphia

18.

Stehr A, Ploner F, Traeger K et al (2005) Plasma disappearance of indocyanine green: a marker for excretory liver function? Intensive Care Med 31:1719–1722PubMedCrossRef

19.

European Association For The Study Of The Liver; European Organisation For Research Treatment Of Cancer (2012) EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56:908–943

20.

Nilsson H, Blomqvist L, Douglas L, Nordell A, Jonas E (2010) Assessment of liver function in primary biliary cirrhosis using Gd-EOB-DTPA-enhanced liver MRI. HPB (Oxford) 12:567–576CrossRef

21.

Tamada T, Ito K, Higaki A et al (2011) Gd-EOB-DTPA-enhanced MR imaging: evaluation of hepatic enhancement effects in normal and cirrhotic livers. Eur J Radiol 80:e311–e316PubMedCrossRef

22.

Dahlqvist Leinhard O, Dahlstrom N, Kihlberg J et al (2012) Quantifying differences in hepatic uptake of the liver specific contrast agents Gd-EOB-DTPA and Gd-BOPTA: a pilot study. Eur Radiol 22:642–653PubMedCrossRef

23.

Geier A, Dietrich CG, Voigt S et al (2003) Effects of proinflammatory cytokines on rat organic anion transporters during toxic liver injury and cholestasis. Hepatology 38:345–354PubMedCrossRef

24.

Geier A, Kim SK, Gerloff T et al (2002) Hepatobiliary organic anion transporters are differentially regulated in acute toxic liver injury induced by carbon tetrachloride. J Hepatol 37:198–205PubMedCrossRef

25.

Planchamp C, Montet X, Frossard JL et al (2005) Magnetic resonance imaging with hepatospecific contrast agents in cirrhotic rat livers. Invest Radiol 40:187–194PubMedCrossRef

26.

Tsuda N, Okada M, Murakami T (2007) Potential of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) for differential diagnosis of nonalcoholic steatohepatitis and fatty liver in rats using magnetic resonance imaging. Invest Radiol 42:242–247PubMedCrossRef

27.

Vavricka SR, Van Montfoort J, Ha HR, Meier PJ, Fattinger K (2002) Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology 36:164–172PubMedCrossRef

28.

Hoekstra LT, de Graaf W, Nibourg GA et al (2013) Physiological and biochemical basis of clinical liver function tests: a review. Ann Surg 257:27–36PubMedCrossRef

29.

Jung GE, Encke J, Schmidt J, Rahmel A (2008) Model for end-stage liver disease. New basis of allocation for liver transplantations. Chirurg 79:157–163PubMedCrossRef

30.

Tripodi A, Chantarangkul V, Primignani M et al (2007) The international normalized ratio calibrated for cirrhosis (INR(liver)) normalizes prothrombin time results for model for end-stage liver disease calculation. Hepatology 46:520–527PubMedCrossRef

31.

Trotter JF, Brimhall B, Arjal R, Phillips C (2004) Specific laboratory methodologies achieve higher model for endstage liver disease (MELD) scores for patients listed for liver transplantation. Liver Transpl 10:995–1000PubMedCrossRef

32.

Marlar RA (2007) Determining the model for end-stage liver disease with better accuracy: neutralizing the international normalized ratio pitfalls. Hepatology 46:295–296PubMedCrossRef

33.

Verloh N, Haimerl M, Zeman F et al (2014) Assessing liver function by liver enhancement during the hepatobiliary phase with Gd-EOB-DTPA-enhanced MRI at 3 Tesla. Eur Radiol 24:1013–1019PubMedCrossRef

34.

Chernyak V, Kim J, Rozenblit AM, Mazzoriol F, Ricci Z (2011) Hepatic enhancement during the hepatobiliary phase after gadoxetate disodium administration in patients with chronic liver disease: the role of laboratory factors. J Magn Reson Imaging 34:301–309PubMedCrossRef

35.

Ichikawa T, Saito K, Yoshioka N et al (2010) Detection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease. Invest Radiol 45:133–141PubMedCrossRef

36.

Ahn SS, Kim MJ, Lim JS, Hong HS, Chung YE, Choi JY (2010) Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma. Radiology 255:459–466PubMedCrossRef

37.

Ringe KI, Husarik DB, Sirlin CB, Merkle EM (2010) Gadoxetate disodium-enhanced MRI of the liver: part 1, protocol optimization and lesion appearance in the noncirrhotic liver. AJR Am J Roentgenol 195:13–28PubMedCrossRef

38.

Katsube T, Okada M, Kumano S et al (2011) Estimation of liver function using T1 mapping on Gd-EOB-DTPA-enhanced magnetic resonance imaging. Invest Radiol 46:277–283PubMedCrossRef

39.

van Montfoort JE, Stieger B, Meijer DK, Weinmann HJ, Meier PJ, Fattinger KE (1999) Hepatic uptake of the magnetic resonance imaging contrast agent gadoxetate by the organic anion transporting polypeptide Oatp1. J Pharmacol Exp Ther 290:153–157PubMed

40.

Weinmann HJ, Ebert W, Misselwitz B, Schmitt-Willich H (2003) Tissue-specific MR contrast agents. Eur J Radiol 46:33–44PubMedCrossRef

41.

Perneger TV (1998) What's wrong with Bonferroni adjustments. BMJ 316:1236–1238PubMedCentralPubMedCrossRef

Titel: Hepatobiliary magnetic resonance imaging in patients with liver disease: correlation of liver enhancement with biochemical liver function tests
verfasst von: Guido M. Kukuk
Stephanie G. Schaefer
Rolf Fimmers
Dariusch R. Hadizadeh
Samer Ezziddin
Ulrich Spengler
Hans H. Schild
Winfried A. Willinek
Publikationsdatum: 01.10.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: European Radiology / Ausgabe 10/2014
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-014-3291-x

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Hepatobiliary magnetic resonance imaging in patients with liver disease: correlation of liver enhancement with biochemical liver function tests